In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Zendy

Xueting Yao | Zendy; Fei Ye | Zendy; Miao Zhang | Zendy; Cheng Cui | Zendy; Baoying Huang | Zendy; Peihua Niu | Zendy; Xu Liu | Zendy; Li Zhao | Zendy; Erdan Dong | Zendy; Chunli Song | Zendy; Siyan Zhan | Zendy; Roujian Lu | Zendy; Haiyan Li | Zendy; Wenjie Tan | Zendy; Dongyang Liu | Zendy

Open Access

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Author(s) -

Xueting Yao,

Fei Ye,

Miao Zhang,

Cheng Cui,

Baoying Huang,

Peihua Niu,

Xu Liu,

Li Zhao,

Erdan Dong,

Chunli Song,

Siyan Zhan,

Roujian Lu,

Haiyan Li,

Wenjie Tan,

Dongyang Liu

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa237

Subject(s) - hydroxychloroquine , covid-19 , severe acute respiratory syndrome coronavirus , medicine , dosing , coronavirus , betacoronavirus , virology , pandemic , respiratory system , in vitro , lopinavir , pharmacology , biology , outbreak , disease , infectious disease (medical specialty) , biochemistry

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research